All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Intermediate- or high-risk myelofibrosis (MF) can be treated with ruxolitinib to reduce spleen size, manage symptoms, and increase survival.1 However, many patients have a suboptimal response to ruxolitinib or relapse over time. Therefore, treatments for post-ruxolitinib failure are currently under investigation.
Here, we summarize a phase II study by Yacoub et al.1 published in Blood Advances which investigates the addition of parsaclisib, a phosphoinositide 3-kinase inhibitor, for patients with MF who responded suboptimally to initial ruxolitinib treatment.
Figure 1. Study design*
QD, once daily; QW, once weekly; Rux, ruxolitinib.
*Adapted from Yacoub, et al.1 Created with BioRender.com.
Figure 2. Median percentage change of spleen volume from baseline, Week 12, and Week 24 in patients treated daily and weekly with parsaclisib after ruxolitinib treatment*
SV, spleen volume.
*Adapted from Yacoub, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox